Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin, currently in development for treatment of anorexia-cachexia syndrom

Lugano, Switzerland, November 12, 2013 - Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly- owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

Related Articles